Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0034 in acute moderate-to-severe generalized pustular psoriasis
CTR20240444Phase 2Completed
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HB0034 in generalized pustular psoriasis (GPP), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Started Feb 2024; status: completed.
02
Drugs
HB0034
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on CTR20240444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240444.